Financial Performance - The group reported unaudited revenue of approximately HKD 7.8 million for the three months ended December 31, 2022, representing an increase of about 4.0% compared to the same period in 2021[5]. - The unaudited gross profit for the same period was approximately HKD 3.3 million, which is an increase of about 13.8% year-on-year[6]. - The group recorded an unaudited net loss of approximately HKD 2.9 million, a decrease of about 31.0% compared to the net loss of HKD 4.2 million in the same period of 2021[7]. - Basic loss per share for the three months ended December 31, 2022, was HKD 0.29, compared to HKD 0.42 for the same period in 2021[8]. - The total comprehensive loss attributable to owners of the company for the three months ended December 31, 2022, was HKD 2.9 million, down from HKD 4.2 million in the previous year[11]. - The company's revenue for the three months ended December 31, 2022, increased by approximately 4.0% to about HKD 7.8 million from HKD 7.5 million in the same period last year[31]. - Gross profit rose by approximately 13.8% to about HKD 3.3 million for the three months ended December 31, 2022, compared to HKD 2.9 million in the previous year[34]. - The net loss attributable to the company's owners for the three months ended December 31, 2022, was approximately HKD 2.9 million, an improvement from a loss of HKD 4.2 million in the same period last year[41]. - Basic and diluted loss per share improved to HKD 0.29 for the three months ended December 31, 2022, compared to HKD 0.42 in the previous year[29]. Revenue Breakdown - Revenue from compliance documents decreased to HKD 2.5 million in Q1 2022 from HKD 3.4 million in Q1 2021, reflecting a decline of approximately 26.3%[20]. - Revenue from periodic report documents increased significantly to HKD 3.4 million in Q1 2022 from HKD 2.2 million in Q1 2021, representing an increase of approximately 55.5%[20]. Expenses and Financial Management - Administrative expenses decreased from approximately HKD 6.4 million to about HKD 5.7 million, mainly due to a reduction in depreciation of right-of-use assets[38]. - Sales expenses decreased from approximately HKD 0.8 million to HKD 0.5 million, primarily due to reduced employee costs[37]. - Other income surged from HKD 28,000 to approximately HKD 219,000, primarily due to a one-time subsidy received under the government's employment support scheme[36]. Dividends and Shareholder Information - The board of directors decided not to declare any dividends for the three months ended December 31, 2022, consistent with the previous year[9]. - The company did not declare any dividends for the three months ended December 31, 2022, consistent with the previous year[47]. - As of December 31, 2022, the company’s major shareholder, Achiever Choice, holds 560,000,000 shares, representing 56% of the company's equity[53]. - Mr. Chan, the chairman and executive director, is deemed to have an interest in the same shares held by Achiever Choice, which he fully owns[50]. - Another significant shareholder, Ms. Yuen, holds 192,200,000 shares, accounting for 19% of the company's equity[53]. - The company has not issued any stock options since the adoption of its stock option plan on January 16, 2018, and there are no unexercised options as of December 31, 2022[56]. - There were no purchases, sales, or redemptions of the company's listed securities during the three months ending December 31, 2022[59]. Corporate Governance - The company has complied with all corporate governance codes as per GEM Listing Rules Appendix 15 during the reporting period[58]. - The audit committee has reviewed the unaudited consolidated results for the three months ending December 31, 2022, ensuring compliance with applicable accounting standards[61]. - No directors or major shareholders have any business interests that compete or may compete with the company’s business as of December 31, 2022[57]. - The company has not disclosed any other interests or positions held by directors or major executives in relation to the company's shares or related securities[54]. - The company is committed to adopting current best practices in corporate governance[58]. Future Outlook - The company plans to explore opportunities in the Greater China region and Southeast Asia to expand its business[32]. - The company remains optimistic about the long-term prospects of the Hong Kong IPO market, benefiting from strong IPO momentum in biotechnology and returning listings[32].
钜京控股(08450) - 2023 Q1 - 季度财报